Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: death (secondary outcome) compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Adverse events: all ‐ central nervous system events (e.g. headache, seizures) (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: all ‐ central nervous system events (e.g. headache,… compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Adverse events: all ‐ other events ‐ not listed above (e.g. dysuria, neck pain, eye discomfort) (secondary outcome) · people with depression after stroke
It is very uncertain whether pharmacological intervention and non‐invasive brain stimulation… changes adverse events: all ‐ other events ‐ not listed above (e.g.… compared with a pharmacological intervention and sham stimulation or usual care… (very low certainty).
1 finding from 1 review
Depression: < 50% reduction in scale scores at end of treatment (primary outcome) · people with depression after stroke
It is very uncertain whether non‐invasive brain stimulation changes depression: < 50% reduction in scale scores at end of treatment… compared with sham non‐invasive brain stimulation and/or usual care (very low certainty).
1 finding from 1 review
Change in depression score ( · adolescents and adults with congenital heart disease
2 findings from 1 review
Treatment success: improvement in the angle of strabismus at 6 months · children with infantile esotropia
It is very uncertain whether surgery changes treatment success: improvement in the angle of strabismus at 6 months compared with botulinum neurotoxin injections (very low certainty).
1 finding from 1 review
Presence and quality of binocularity at 6 months · children with infantile esotropia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects (severe, minor) at 6 months · children with infantile esotropia
1 finding from 1 review
Treatment success: improvement in the angle of strabismus at 6 months · children with infantile esotropia
1 finding from 1 review
Presence and quality of binocularity at 6 months · children with infantile esotropia
1 finding from 1 review
Adverse effects (severe, minor) at 6 months · children with infantile esotropia
1 finding from 1 review
Persistent kidney disease at any time after treatment · patients with IgAV
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 3 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
2 findings from 1 review
Children with any continuing kidney disease at 6 months · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
1 finding from 1 review
Any continuing kidney disease at 12 months (study with high risk of bias excluded) · patients with IgAV
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
2 findings from 1 review
Number developing severe kidney disease · patients with IgAV
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
1 finding from 1 review
Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema
Systemic aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).
1 finding from 1 review
Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution of primary hemorrhage · people with traumatic hyphema
1 finding from 1 review